GLOBAL RESEARCH ARCHIVE
Astera Labs Inc: Substantial upside driven by the Scorpio X ramp
Research evidence excerpt
M
Idea
August 5, 2026 02:41 AM GMT
Morgan Stanley & Co. LLC
Astera Labs Inc | North America
Joseph Moore
Equity Analyst
Substantial upside driven by the
Scorpio X ramp
Ella Tulchinsky
Research Associate
Mason Wayne
Research Associate
What’s Changed
Astera Labs Inc (ALAB.O)
From
To
Price Target
$335.00
$382.00
Shane Brett
Equity Analyst
Nicole Kozhukhov
Research Associate
AlphaSignals Earnings Reaction
Strengthens our thesis
Meaningful upside
Meaningful revision higher
Impact to our thesis
Financial results versus consensus
Direction of next 12-month
consensus EPS
Source: Company data, Morgan Stanley Research
Astera guides 3q revenues to $550M vs. consensus $417M as
the switch cycle takes off in earnest and other parts of the
business remain robust. Customer concentration and
repeatability continue to be debated but the company continues
to execute.
Key Takeaways
Q3 guide implies ~40% q/q growth, with Scorpio becoming the largest product
family as the lead X-Series program enters volume production.
Astera Labs Inc (ALAB.O, ALAB US)
Semiconductors | United States of America
Stock Rating
Industry View
Price target
Shr price, close (Aug 4, 2026)
Mkt cap, curr (mm)
52-Week Range
12/25 12/26e 12/27e 12/28e
EPS ($)**
Prior EPS ($)**
P/E
EPS ($)§
Div yld (%)
1.84
175.0
1.78
broaden the growth runway beyond the initial Scorpio ramp.
Quarter
2025
Q1
Q2
Q3
Q4
0.33
0.44
0.49
0.58
Stay OW, raise PT to $382
3.99
2.88
144.1
3.07
5.83
3.70
97.0
4.56
6.93
4.22
79.4
5.93
Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare
framework
** = Based on consensus methodology
§ = Consensus data is provided by Refinitiv Estimates
e = Morgan Stanley Research estimates
Quarterly EPS ($)
platforms; we still view Trainium4 as a key socket to watch.
Overweight
Attractive
$382.00
$361.67
$70,525
$499.48-97.89
Fiscal Year Ending
CY27 revenue rises to nearly $3B as UALink, CXL, optical and custom solutions
Amazon concentration remains the key risk, though exposure spans multiple
2026e 2026e
Prior Current
0.73
0.84
0.61a
0.80a
1.19
1.39
2027e 2027e
Prior Current
0.88
0.91
0.95
0.96
1.38
1.45
1.61
e = Morgan Stanley Research estimates, a = Actual Company reported data
…
The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.
Open report viewer